Immunologic Factor
IO Biotech Sheds 50% of Staff After FDA Blocks Cancer Vaccine Approval Path
IO Biotech; layoffs; cancer vaccine; FDA rejection; Cylembio; Phase 3 trial; melanoma; regulatory setback; cost cutting; clinical trial
Genmab CEO on the $8B Acquisition of Merus: Strategy Behind the ‘Very Fair’ Deal and Plans to Polish a Rough Diamond
Genmab; Merus; petosemtamab; acquisition; oncology; head and neck cancer; bispecific antibody; FDA Breakthrough Therapy; pipeline expansion; biotech; $8B deal; CEO perspective
GSK Appoints Luke Miels as New CEO, Succeeding Emma Walmsley on Jan. 1, 2026
GSK; Luke Miels; Emma Walmsley; CEO appointment; pharmaceuticals; leadership transition; specialty medicines; vaccines; R&D pipeline
MoonLake shares crash after mixed results in pivotal hidradenitis suppurativa studies
MoonLake Immunotherapeutics; Sonelokimab; hidradenitis suppurativa; Phase 3 trial; clinical trial results; biotech shares; placebo response; drug approval outlook; IL-17 inhibitors; Bimzelx; Cosentyx; drug market potential
Tourmaline Attracted Bidding War Before $1.4B Acquisition by Novartis
Tourmaline Bio; Novartis; acquisition; bidding war; $1.4 billion; pacibekitug; cardiovascular drug; IL-6 antibody; ASCVD; biotech
Continuous Bioprocessing for Bispecific Antibodies: Innovations Accelerating Therapeutic Antibody Production (2024–2025)
continuous bioprocessing; bispecific antibodies; therapeutic antibody production; bioprocess innovation; high-throughput production; antibody engineering; scale-up; oncology therapeutics; protein purification; automation
GSK CEO Emma Walmsley Steps Down After 9 Years; Luke Miels to Succeed
Emma Walmsley; GSK; CEO transition; Luke Miels; leadership change; pharmaceutical industry; Haleon demerger; specialty medicines; vaccines; succession planning
Eli Lilly Withdraws $1.9B Phase 2b Obesity Trial Before Launching Enrollment
Eli Lilly; obesity drug; tirzepatide; bimagrumab; trial termination; phase 2b; Zepbound; type 2 diabetes; clinical trial; regulatory strategy
FDA Rejects Scholar Rock’s SMA Drug Due to Catalent Indiana Manufacturing Issues
FDA; Scholar Rock; Apitegromab; SMA; Spinal Muscular Atrophy; Catalent Indiana; Complete Response Letter; Manufacturing issues; Drug approval
Fierce Biotech Fundraising Tracker ’25: Avenzo adds $60M Series B; Ollin debuts with $100M
Avenzo Therapeutics; Series B financing; Ollin Biosciences; biotech fundraising; oncology; ophthalmology; venture capital; pipeline development; bispecific antibody; clinical trials